Nausea

Pipeline Programs

Companies

Clinical Trials

1 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

1100%

+ 36 programs with unclassified modality

Competitive Landscape

11 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

MSDIreland - Ballydine

13 programs

AprepitantPhase 41 trial

MK0869, aprepitant / Duration of Treatment: 3 daysPhase 41 trial

Standard POPhase 41 trial

+8 more programs

Active Trials

NCT00717054Completed115Est. Mar 2010

NCT00659737Completed115Est. Mar 2010

NCT00514878Completed2,000Est. Nov 2008

+10 more trials

Sharp TherapeuticsPA - Pittsburgh

13 programs

AprepitantPhase 4

MK0869, aprepitant / Duration of Treatment: 3 daysPhase 4

Standard POPhase 4

+8 more programs

ViiV HealthcareNC - Durham

1 program

OndansetronPhase 4

HelsinnIreland - Dublin

1 program

Fosaprepitant dimegluminePhase 31 trial

Active Trials

NCT01074697Completed246Est. Apr 2015

AstraZenecaCAMBRIDGE, United Kingdom

1 program

esomeprazolePhase 3Small Molecule1 trial

Active Trials

NCT00206440Terminated43Est. Feb 2012

Prevail TherapeuticsNY - New York

1 program

LY3537021Phase 21 trial

Active Trials

NCT07169851Recruiting204Est. Feb 2027

SandozAustria - Kundl

2 programs

Ondansetron HCl 24 mg TabletsPhase 11 trial

Active Trials

NCT00946387Completed26Est. Sep 2004

NCT00947128Completed26Est. Oct 2004

Merck & Co.RAHWAY, NJ

2 programs

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)N/A

MK0869, aprepitant / Duration of Treatment: 3 daysPHASE_3

Nielsen BioSciencesCA - San Diego

1 program

Sevoflurane-remifentanil anaesthesiaN/A1 trial

Active Trials

NCT00452855Completed160Est. May 2005

TakedaTOKYO, Japan

1 program

OndansetronPHASE_21 trial

Active Trials

NCT02006056Completed30Est. Jun 2014

GSKLONDON, United Kingdom

1 program

OndansetronPHASE_41 trial

Active Trials

NCT00429832Completed120Est. Nov 2005

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

MSDAprepitant

MSDMK0869, aprepitant / Duration of Treatment: 3 days

GSKOndansetron

MSDStandard PO

MSDMK0869, aprepitant / Duration of Treatment: 3 days

HelsinnFosaprepitant dimeglumine

AstraZenecaesomeprazole

MSDMK0869, aprepitant / Duration of Treatment: 3 days

Prevail TherapeuticsLY3537021

MSDaprepitant

TakedaOndansetron

MSDFosaprepitant dimeglumine

MSDaprepitant, ondansetron, dexamethasone

SandozOndansetron HCl 24 mg Tablets

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 6,242 patients across 21 trials

NCT00429754 MSDAprepitant

Pharmacokinetic Study of Aprepitant in BEP Treatment of Patients With Testis Carcinoma (A-BEP)

Est. completion: Sep 20080

Phase 4Withdrawn

NCT01636947 MSDAprepitant

A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)

Start: Dec 2012Est. completion: Aug 2014494 patients

Phase 4Completed

NCT00090207 MSDMK0869, aprepitant / Duration of Treatment: 3 days

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

Start: Jan 2004Est. completion: Sep 2004477 patients

Phase 4Completed

NCT00429832 GSKOndansetron

A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department

Start: Oct 2003Est. completion: Nov 2005120 patients

Phase 4Completed

NCT00781768 MSDStandard PO

Odansetron and Dexamethasone Alone vs. Odansetron, Dexamethason and Apreptant to Prevent Nausea

Start: Aug 2003Est. completion: Jul 2010181 patients

Phase 4Completed

NCT00092183 MSDMK0869, aprepitant / Duration of Treatment: 3 days

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Start: Oct 2002Est. completion: Feb 2004866 patients

Phase 4Completed

NCT01074697 HelsinnFosaprepitant dimeglumine

Efficacy of Two Antiemetic Regimens in Patients Receiving Radiotherapy and Concomitant Weekly Cisplatin

Start: Apr 2010Est. completion: Apr 2015246 patients

Phase 3Completed

NCT00206440 AstraZenecaesomeprazole

Nexium Study To Suppress Nausea During Chemotherapy

Start: Aug 2005Est. completion: Feb 201243 patients

Phase 3Terminated

NCT00092196 MSDMK0869, aprepitant / Duration of Treatment: 3 days

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

Start: Dec 2002Est. completion: Dec 2004820 patients

Phase 3Completed

NCT07169851 Prevail TherapeuticsLY3537021

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Start: Nov 2025Est. completion: Feb 2027204 patients

Phase 2Recruiting

NCT01450826 MSDaprepitant

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Start: Jun 2014Est. completion: Apr 2017136 patients

Phase 2Completed

NCT02006056 TakedaOndansetron

Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting

Start: Nov 2013Est. completion: Jun 201430 patients

Phase 2Completed

NCT01405924 MSDFosaprepitant dimeglumine

Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)

Start: Oct 2011Est. completion: Dec 2013111 patients

Phase 2Terminated

NCT00711555 MSDaprepitant, ondansetron, dexamethasone

Emend for Multiple-day Emetogenic Chemotherapy

Start: Nov 2005Est. completion: Jan 200922 patients

Phase 2Completed

NCT00946387 SandozOndansetron HCl 24 mg Tablets

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Fasting Conditions

Start: Sep 2004Est. completion: Sep 200426 patients

Phase 1Completed

NCT00947128 SandozOndansetron HCl 24 mg Tablets

To Demonstrate the Relative Bioavailability Study of Ondansetron HCl 24 mg Tablets Under Non-Fasting Conditions

Start: Sep 2004Est. completion: Oct 200426 patients

Phase 1Completed

NCT00835965 MSDDexamethasone

Oral Aprepitant and Lower Dose Dexamethasone Versus Aprepitant Alone for Preventing Postoperative Nausea and Vomiting (PONV) After Elective Laparoscopic Surgeries

Start: Feb 200950 patients

N/AUnknown

NCT00659737 MSDAprepitant

Comparison of Oral Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Start: Apr 2008Est. completion: Mar 2010115 patients

N/ACompleted

NCT00717054 MSDAprepitant

Comparison of Aprepitant Versus Aprepitant and Transdermal Scopolamine for Preventing Postoperative Nausea and Vomiting

Start: Feb 2008Est. completion: Mar 2010115 patients

N/ACompleted

NCT00514878 MSDDevelopment of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Development of a Predictive Model for Post-Discharge Nausea and Vomiting (PDNV)

Start: Aug 2007Est. completion: Nov 20082,000 patients

N/ACompleted

NCT00452855 Nielsen BioSciencesSevoflurane-remifentanil anaesthesia

Sevoflurane-Remifentanil Anaesthesia. The Risk of Post Operative Nausea

Start: Jan 2002Est. completion: May 2005160 patients

N/ACompleted

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

4 late-stage (Phase 3) programs, potential near-term approvals

1 actively recruiting trials targeting 6,242 patients

12 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.